Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Hematologic Neoplasms × lenvatinib × Clear all

Phase

Phase 3 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Carcinoma, Hepatocellular 19 Parkinson Disease 4, Autosomal Dominant Lewy Body 13 Carcinoma, Renal Cell 5 Squamous Cell Carcinoma of Head and Neck 2 Melanoma 2 Endometrial Neoplasms 2 von Hippel-Lindau Disease 1 Thyroid Neoplasms 1 Recurrence 1 Neoplasms 1 Liver Neoplasms 1 Kidney Neoplasms 1 Hematologic Neoplasms 1 Esophageal Squamous Cell Carcinoma 1 Colorectal Neoplasms 1 Cholangiocarcinoma 1 Carcinoma, Transitional Cell 1 Carcinoma, Non-Small-Cell Lung 1 Advanced Malignancies 1 Advanced Endometrial Cancer 1

Interventions

Olanzapine 4 Cyclophosphamide 4 Voriconazole 3 Tranexamic Acid 3 Standard of Care 3 Zoledronic Acid 2 Practice Guidelines as Topic 2 Methods 2 Educational Status 2 Early Intervention, Educational 2 Doxorubicin 2 trihexyltetradecylphosphonium chloride 1 thymoglobulin 1 shengxuening 1 pembrolizumab 1 olaparib 1 letermovir 1 lenvatinib 1 fludarabine phosphate 1 ferrous succinate 1 fedratinib 1 cilgavimab and tixagevimab drug combination 1 apixaban 1 Whole-Body Irradiation 1 Vincristine 1 Thalidomide 1 Tazobactam 1 Specimen Handling 1 Sirolimus 1 Piperacillin, Tazobactam Drug Combination 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03486873 2026-03-16

MK-3475-587

Merck Sharp & Dohme LLC

Phase 3 Recruiting

Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡